Steve MacMillan, David LaVance
Hologic President and CEO Steve MacMillan has been appointed chairman of the company's board, following the resignation of David LaVance, who has told the board he will not stand for reelection at the 2016 annual shareholders' meeting. LaVance has been on Hologic's board since 2002.
Additionally, Elaine Ullian, a current director at Hologic, has been appointed the lead independent director. Ullian is the former president and CEO of the Boston Medical Center.
Pierre Meulien will step down as president and CEO of Genome Canada on July 17 to become the executive director of the Innovative Medicines Initiative in Belgium. Meulien has been with Genome Canada since October 2010. The organization has begun a global search for his successor. Cindy Bell, a member of Genome Canada's executive management team, will serve as its president and CEO on an interim basis.
Emmanuelle Charpentier, Jennifer Doudna
The Gruber Foundation at Yale University announced that Emmanuelle Charpentier and Jennifer Doudna will receive the 2015 Gruber Genetics Prize. Charpentier, a professor at the Helmholtz Centre for Infection Research in Germany, and Doudna, a professor of biochemistry at the University of California, Berkeley, are co-creators of the CRISPR/Cas9 genome editing technology.
They will receive the $500,000 award in Baltimore on Oct. 9 at the annual meeting of the American Society of Human Genetics.
Gary Huff is joining Baylor Miraca Genetics Laboratories as its president and CEO. He was previously president executive vice president and COO of Solstas Lab Partners. Before that Huff was a senior executive at Laboratory Corporation of America, where at different points, he was the firm's North Atlantic Division senior vice president; national toxicology SVP; VP of national sales and marketing operations; and executive director of business development.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.